Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...

Treatment with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, can result in the formation of antibodies against infliximab. We evaluated the clinical significance of ...

Please provide your email address to receive an email when new articles are posted on . Remicade trough levels 2 weeks after infusion were significantly lower in patients with acute severe ulcerative ...